WA
ABVX icon

Whipplewood Advisors’s Abivax ABVX Stock Holding History

Whipplewood Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53K Sell
19
-43
-69% -$4.87K ﹤0.01% 387
2026
Q1 		$6.9K Buy
+62
New +$7.34K ﹤0.01% 555

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Whipplewood Advisors's ABVX Position: Q2 2026 in Review

Whipplewood Advisors reduced its Abivax (ABVX) stake by 69% in Q2 2026, selling an estimated $4.87K and leaving 19 shares worth $2.53K. The position accounts for ﹤0.01% of the portfolio, ranked #387.

Whipplewood Advisors first reported a position in ABVX in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.9K in Q1 2026. 304 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Whipplewood Advisors held 19 shares of Abivax worth $2.53K as of Q2 2026.
  • Whipplewood Advisors sold 43 Abivax shares in Q2 2026, an estimated $4.87K.
  • Abivax made up ﹤0.01% of Whipplewood Advisors's portfolio in Q2 2026, its #387 holding.
  • Whipplewood Advisors first reported a position in Abivax in Q1 2026 and has held it in 2 quarters since.
  • Whipplewood Advisors's Abivax position peaked at $6.9K in Q1 2026.
  • 304 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.